Abstract Library

#4497 Complex management of a long-term gastrinoma survivor with multimodal treatment approaches

Introduction: The prognosis of pancreatic gastrinomas is influenced by tumour burden, extent of metastasis, and treatment response, with 5-year survival rates ranging from 20% to 40%. Treatment for well-differentiated tumours typically include locoregional therapies, long-acting somatostatin analogues, molecular targeted agents, radionuclides, and chemotherapy.

Conference:

Presenting Author: Puscasu A

Authors: Puscasu A, Miron M, Croitoru A,

Keywords: gastrinoma, neuroendocrine tumour, long survival, complex management,

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#3865 Prospective observational study on third-line treatments in neuroendocrine carcinoma – Data from the phase II SENECA trial

Introduction: Neuroendocrine Carcinoma (NEC) are very rare and characterized by a poor prognosis. Therapeutic opportunities for metastatic disease beyond the first line are very limited.

Conference:

Presenting Author: Liverani C

Authors: Bongiovanni A, Liverani C, Morbini S, Pusceddu S, Gelso F,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, third line, chemotherapy,

#3571 A multicentric randomized phase II trial of CAPTEM (CT) or Folfiri (F) as second-line therapy in neuroendocrine carcinomas (NEC) and exploratory analysis of predictive role of PET imaging and biological markers (SENECA Study)

Introduction: No standard 2nd line treatment has been validated in patients (pts) with metastatic or locally advanced, non-resectable, grade 3 gastroenteropancreatic (GEP) and lung NEC after first-line platinum therapy. Furthemore more accurate prognostic biomarkers are needed.

Conference:

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Foca F, Bergamo F, Leo S, Pusceddu S,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, second line, Phase 2, NEC, Temozolomide, Capecitabine,

#3403 Trends in chemotherapy use in neuroendocrine neoplasms: One step beyond guidelines

Introduction: The therapeutic landscape of neuroendocrine neoplasms (NENs) is constantly evolving. Current guidelines reflect the complexity of treatment sequences and mainly incorporate evidence from phase 3 clinical trials. Chemotherapy (CT) is a valuable option for patients with lung, pancreatic, and high-grade NENs, but proper phase 3 randomized studies are an unmet need. Nevertheless, several phase 2 studies with CT have been presented and published in the last year, with impact in both clinical practice and guidelines.

Conference:

Presenting Author:

Authors: Hernando J, Garcia-Diaz H, Bellas Fernandez L, Garcia Alvarez A, Roca M,

Keywords: Chemotherapy, CAPTEM, GUIDELINES,